Physician profile
Timothea A Ryan
NPI 1427170596
$9,375.40
in general payments reported to CMS, 2019-2025
24 companies · $3,347 in 2025
The $3,347 reported for 2025 was more than what 92% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $700 · 2020: $291 · 2021: $494 · 2022: $1,597 · 2023: $1,387 · 2024: $1,561 · 2025: $3,347.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,044 · Consulting Fee: $1,250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,043.91 |
| Consulting Fee | $1,250.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,043.93 | 2022-2025 | Durysta, Xen Glaucoma Treatment System, Alphagan P |
| Glaukos Corporation | $1,513.73 | 2022-2025 | Istent Inject Trabecular Micro-Bypass System Model G2-M-Is, Idose |
| Bausch & Lomb Americas INC. | $941.28 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Sight Sciences, INC. | $760.81 | 2022-2025 | Omni Surgical System, Sion Surgical Instrument |
| Alcon Vision LLC | $627.45 | 2019-2025 | Clareon, Rocklatan, Tryptyr |
| Allergan, INC. | $613.66 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $490.59 | 2023-2025 | Cequa |
| Johnson & Johnson Surgical Vision, INC. | $330.72 | 2021-2024 | Tecnis Simplicity, Tecnis Iol, Tecnis Iol |
| Tarsus Pharmaceuticals, INC. | $325.15 | 2024-2025 | Xdemvy |
| Aerie Pharmaceuticals, INC. | $269.75 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $227.41 | 2019-2021 | |
| Oyster Point Pharma, INC. | $163.28 | 2022-2025 | Tyrvaya, Ryzumvi |
| Omeros Corporation | $162.42 | 2020-2021 | |
| Ocular Therapeutix, INC. | $154.62 | 2022-2025 | Dextenza |
| Novartis Pharmaceuticals Corporation | $141.18 | 2022-2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $134.64 | 2025 | Light Adjustable Lens (Lal), Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd) |
| Rayner Intraocular Lenses Limited | $125.87 | 2022-2024 | Rayone Aspheric, Rayone Emv, Rayone Spheric |
| Harrow Eye, LLC | $105.78 | 2025 | Vevye |
| Dompe US, INC. | $82.83 | 2025 | Oxervate |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $63.90 | 2019-2021 | |
| Ivantis, INC | $33.83 | 2020 | |
| Amgen INC. | $23.00 | 2024 | Tepezza |
| Thea Pharma INC. | $20.07 | 2023 | Iyuzeh |
| Carl Zeiss Meditec Cataract Technology INC. | $19.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothea Ryan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.